Press Room
Press Room 2023Press Releases 2023
Sunday, 10 September 2023 04:11
Treatment of Osteoarthritis with MesenCure™ Reduces Pain and Enhances Load-Bearing Capacity by 86% in Preclinical Trials.
Results Presented at the International Conference – Advanced Therapies Europe 2023 Bonus Biogroup is pleased to announce the successful demonstration of MesenCure's effectiveness in treating osteoarthritis in preclinical trials (hereafter: "the trial for osteoarthritis treatment") [1]. This achievement follows a clinical trial that underscored MesenCure's success in mitigating inflammation and…
Sunday, 27 August 2023 12:14
World's First Successful Joint Fusion with BonoFill™: A Lab-Grown Human Bone Graft by Bonus Biogroup Eliminates Self-Bone Transplantation in Phase II Clinical Trial for Limb Bone Defects.
World's First Successful Joint Fusion with BonoFill™: A Lab-Grown Human Bone Graft by Bonus Biogroup Eliminates Self-Bone Transplantation in Phase II Clinical Trial for Limb Bone Defects. Success Reported in a Keynote Presentation at the World Orthopedics Conference 2023. Bonus Biogroup proudly announces a global first: the successful fusion of…
Sunday, 18 June 2023 17:57
Significant Progress in Doubling Survival Rates with MesenCure Following Exposure to Potentially Lethal Chemotherapy Drugs, According to Preclinical Trials.
Bonus Biogroup Showcased Breakthrough Trial Results at International Drug Development Seminar at the invitation of Jackson Laboratory, USA. Bonus Biogroup is delighted to announce the successful preclinical demonstration [1] of MesenCure's effectiveness in treating lethal toxicity induced by chemotherapy drugs, such as Cisplatin and Bleomycin, routinely used in cancer treatment.…
Monday, 12 June 2023 12:47
Phase II Clinical Trial Reports Complete Success in 90% of Patients Treated for Facial Bone Deficiency with Company-developed Living Human Bone Grafts Reducing Recovery Time by Half, Based on Interim Results from 20-out-of-30 Procedures.
Company Showcased Bone Regeneration Success at ICOMS 2023, Following Invitation from the International Association for Oral and Maxillofacial Surgery. Bonus Biogroup is pleased to announce the compelling findings after the six-month follow-up period for twenty out of thirty transplants of BonoFill, our living human bone graft, in Phase II Clinical…
Wednesday, 31 May 2023 05:11
The Success of Bonus Biogroup's Bioinformatics: Leveraging AI to Streamline Cell Therapy
Bonus Biogroup's Bioinformatics Unit presents its first achievements at the Paris 2023 annual meeting of the International Society for Cell and Gene Therapy (ISCT), highlighting accomplishments across various R&D programs. Bonus BioGroup (TASE: BONS), a clinical-stage Israeli biotechnology company engaged in research and development of biomedical tissue-engineered and cell therapy…
Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is pleased to announce entering an advanced stage in a joint trial in partnership with the Israel Institute for Biological Research (the "IIBR"). This study explores,…
Monday, 10 April 2023 15:00
Jackson Laboratories, USA, in collaboration with University College London Hospital, hosted a seminar in which Bonus Biogroup presented results demonstrating that:
The drug MesenCure reduced life-threatening cytokine release syndrome, which occurred as a result of immunotherapy for the treatment of cancer Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is pleased to announce that Jackson…
Sunday, 26 February 2023 15:02
Bonus Biogroup Partners with St. Catherine's Hospital to Advance Clinical Trials of BonoFill and MesenCure in Europe
Collaboration with one of Europe's leading research centers in personalized medicine aims to accelerate clinical development. Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is delighted to announce the signing of a strategic cooperation…
Thursday, 26 January 2023 14:56
Presentations to Highlight the Success of BonoFill at the 42nd Annual Conference of the Israeli Orthopedic Association
Orthopedic Surgeons to Showcase Successful Treatment of Bone Deficiencies with BonoFill, a Live Human Bone Graft by Bonus Biogroup Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is pleased to announce that orthopedic surgeons…
Sunday, 15 January 2023 14:46
Success in obtaining certification of compliance with industrial manufacturing standards for Phase III clinical trial in severe COVID patients
The Israel Ministry of Health certified the facility and process for producing the investigational drug MesenCure to comply with Good Manufacturing Practices (GMP) according to the recommendations of the World Health Organization. Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered…
BONUS BIOGROUP LTD.
info@bonus-bio.com
+972 (0)73 206 7104
Matam Advanced Technology
Park P.O.B 15143 Haifa 31905 Israel
 |
 |
 |
 |
© 2022 Bonus BioGroup Ltd. Created By Netron Israel Ltd